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ABSTRACT 
Objective: The present work was undertaken with an aim to develop and validate a rapid reverse-phase high-performance liquid chromatography 
(RP-HPLC) method for the estimation of curcumin and cyclosporine in the capsule dosage form. 
Methods: The RP-HPLC method for the simultaneous estimation of curcumin and cyclosporine was developed using Agilent (Infinity 1260) HPLC 
system and Eclipse XDB-C18 (4.6 x 150 mm i.d., 5µ) stationary phase. The optimized mobile phase comprised of acetonitrile: water: methanol (50: 
10: 40 v/v/v) pumped at a flow rate of 0.5 ml/min. Separation of drugs was achieved in an isocratic mode and elution was monitored using PDA 
detector at 214 nm. The method was validated as per ICH-Q2R1 guidelines.  
Results: Retention time of the curcumin and cyclosporine were found to be 3.073 min and 6.373 min with the correlation coefficient (R2) of 0.9993 
and 0.998 respectively. The response of curcumin and cyclosporine was found linear in the concentration range of 8-48 μg/ml and 4-24 μg/ml 
respectively. The percent recovery values were found in the range of 97-103% indicating satisfactory accuracy of the method. The percent relative 
standard deviation (% RSD) values for the precision study was less than 2 which suggest that the method is precise.  
Conclusion: The proposed method was found accurate, precise and specific for the determination of curcumin and cyclosporine in bulk as well as in 
capsule dosage form. Thus, the present method can be used for routine analysis and quality control of curcumin and cyclosporine in bulk and 
capsule dosage form. 
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Chemically, curcumin is (1E, 6E)-1,7-bis (4-hydroxy-3-methoxyphenyl)-
1,6-heptadiene-3,5-dione [1]. Literature survey revealed LC-MS [2], RP-
HPLC [2], HPTLC [3], stability indicating HPLC [4], and UV 
spectrophotometric [1, 5-7] methods for estimation of curcumin alone or 
in combination with other drugs in bulk, in dosage forms and human 
plasma. Cyclosporine is an immunosuppressant drug used in post 
allogenic organ transplant to reduce the activity of patient's immune 




11,14,17, 20, 23, 26, 29, 32-undecone [8]. Several bioanalytical methods 
which include RP-HPLC [8], LC-MS [8] and RP-HPLC [8] were also 
reported for the analysis of cyclosporine in soft gelatin capsule dosage 




Fig. 1: Molecular structure of (a) curcumin and (b) cyclosporine 
 
Till date, RP-HPLC method was not developed for the simultaneous 
estimation of curcumin and cyclosporine in the pharmaceutical 
dosage form. Therefore, the present study was attempted to develop 
a simple, accurate, precise and specific RP-HPLC method for 
quantitative determination of curcumin and cyclosporine in capsule 
dosage form for management of inflammatory bowel disorder (IBD). 
There is no marketed formulation of curcumin and cyclosporine 
(pellets in a capsule or any other pharmaceutical dosage form) for 
the management of IBD. The literature states that curcumin and 
cyclosporine, when used in combination, can successfully manage 
the remission of ulcerative colitis [9]. Therefore, a fixed-dose 
combination capsule formulation containing bioadhesive pellets of 
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curcumin and cyclosporine was developed in-house. The developed 
and optimized formulation of bioadhesive pellets containing 
curcumin and cyclosporine was selected for in vitro drug release 
study.  
MATERIALS AND METHODS 
Curcumin and cyclosporine were procured from Otto Chemie Pvt. 
Ltd., Mumbai, India and Concord Biotech Limited Ahmedabad, India 
respectively. HPLC grade acetonitrile and methanol were procured 
from SD Fine Chemical Ltd., Mumbai, India. Millipore water was used 
for the preparation of chemicals/solutions. 
HPLC instrumentation and chromatographic conditions 
Analytical chromatography was performed on a Agilent HPLC 
system (Infinity 1260) equipped with auto-sampler and photo diode 
array (PDA) detector. Chromatographic separation of curcumin and 
cyclosporine was achieved on Eclipse XDB-C18 (4.6 x 150 mm, 5 µ 
particle size) column at a temperature of 70 °C±0.02 °C. The mobile 
phase comprised of acetonitrile: water: methanol (50:10:40 v/v/v). 
The flow rate was at 0.5 ml/min., drug peaks were detected at 214 
nm with an injection volume of 20 µl.  
Preparation of standard solutions 
Preparation of stock solution 
Stock solutions were prepared by dissolving 10 mg of curcumin and 
10 mg of cyclosporine in 10 ml of methanol separately and subjected 
to sonication to give an individual concentration of 1000 µg/ml.  
Method development 
Aliquots of the standard stock solutions were further diluted with 
mobile phase to get 24 µg/ml of curcumin and 12 µg/ml of 
cyclosporine. The samples were injected in the HPLC system and 
chromatograms were recorded. Various combinations of mobile 
phase components, column temperature, and columns were tried to 
get desirable resolved peaks.  
Method validation  
System suitability  
The system suitability test is used to verify that the chromatographic 
system is suitable for the intended analysis or not. The system 
suitability of the method was checked by injecting six different 
injections of 24 µg/ml of curcumin and 12 µg/ml of cyclosporine. 
Various parameters like tailing factor, theoretical plates, peak area 
and resolution were checked according to USP criteria [10, 11]. 
Specificity 
Specificity is the ability to measure accurately and specifically the 
analyte of interest in the presence of other components that may be 
expected to be present in the sample matrix. Specificity was carried by 
dissolving 500 mg of placebo sample (pellets made up of excipients 
viz. avicel PH 101, carbopol 940, hydroxypropyl cellulose-H and 
sodium chloride excluding both the drugs) in 100 ml of mobile phase.  
Precision 
Precision was studied at three levels: repeatability, intermediate 
precision, and reproducibility.  
Repeatability: Repeatability study was performed by preparing a 
minimum of six determinations (n=6) of test concentration 
(curcumin 24 µg/ml: cyclosporine 12 µg/ml) and was analyzed. It is 
expressed as the percent relative standard deviation (% RSD). 
Intermediate Precision: The extent to which intermediate precision 
should be established depends on the circumstances under which 
the procedure is intended to be used. This study was done at two 
levels (intra-day and inter-day study). Intra-day precision was done 
by preparing the test concentration (curcumin 24 µg/ml and 
cyclosporine 12 µg/ml) and assaying for six times (n=6) at 3 
different time intervals. Inter-day precision was done by analyzing 
samples (n=6) for three consecutive days. The percent relative 
standard deviation (% RSD) values were calculated. 
Accuracy  
This study was carried out by spiking standard solution of curcumin 
and cyclosporine to the placebo. Placebo was prepared containing 
avicel PH 101, carbopol 940, hydroxypropyl cellulose-H and sodium 
chloride which were further coated with Eudragit S100 as enteric 
coating polymer using isopropyl alcohol and acetone in the ratio of 
1:1 [12-15]. This placebo batch was selected for the accuracy studies 
since marketed formulation containing both the drugs was not 
available. Concentrations of curcumin and cyclosporine 
corresponding to 80%, 100%, and 120% were added to 1 ml 
solution of pre-analyzed placebo formulation and percent recovery 
of drug-spiked was determined. The study was performed in 
triplicates and mean % RSD was determined.  
Linearity and range 
The linearity of an analytical procedure is its ability (within a given 
range) to obtain test results which are directly proportional to the 
concentration (amount) of analyte in the sample. It is generally reported 
as the variance of slope or regression line. A range is an interval between 
the upper and lower concentrations of solute that have been 
demonstrated to be determined with precision, accuracy, and linearity. 
To establish the linearity of this method 8-48 μg/ml for curcumin and 4-
24 μg/ml for cyclosporine was prepared from the stock solution and 
analysed. Each concentration measurement was performed in triplicate. 
Peak areas were plotted versus respective concentrations and linear 
regression analysis was performed on the resultant curves.  
LOD and LOQ 
Limit of detection (LOD) and limit of quantification (LOQ) decide the 
sensitivity of the method. LOD is the lowest detectable concentration 
of the analyte by the method while LOQ is the minimum quantifiable 
concentration. ICH defines the detection limit of an individual 
analytical procedure as the lowest amount of analyte in a sample 
which can be detected but not necessarily quantitated as an exact 
value. The LOD is the point at which a measured value is larger than 
the uncertainty associated with it. The quantitation limit is a 
parameter of quantitative assays for low levels of compounds in 
sample matrices and is used particularly for the determination of 
impurities or degradation products. LOD and LOQ were calculated 
from standard calibration curves of drugs using following equations- 
 




The robustness of an analytical procedure is a measure of its 
capacity to remain unaffected by small but deliberate variations in 
method parameters and provides an indication of its reliability 
during its normal usage. The test concentration of curcumin and 
cyclosporine (curcumin 24 µg/ml and cyclosporine 12 µg/ml) were 
injected by changing the chromatographic conditions. Following 
changes were made to check the reliability of the method. The study 
was performed in triplicate.  
Variation of flow rate: The chromatographic responses were 
recorded by a change in the flow rate to 0.4 ml/min to 0.6 ml/min. 
Variation in temperature: The chromatograms of curcumin and 
cyclosporine was measured by a change in the temperature to 69 °C 
to 71 °C. 
Drug content 
The bioadhesive pellets were triturated using mortar and pestle and 
the powder blend equivalent to 30 mg of drug (curcumin 20 mg and 
cyclosporine 10 mg) was dispersed in 10 ml of distilled water in 10 
ml amber colored volumetric flask. The resultant dispersion was 
filtered after an appropriate interval of time (for the drug to come 
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into the medium) to give a clear solution. An aliquot of 1 ml was 
withdrawn from this solution and diluted up to 10 ml. The percent of 
drug content was determined. 
In vitro dissolution study 
The in vitro release of drug from the bioadhesive pellets was 
investigated using USP Type 1 dissolution test apparatus (Basket 
type, Electrolab) at a rotational speed of 100 rpm. 500 mg of pellets 
in size 0 hard gelatin capsule shell equivalent to 30 mg of drug was 
placed in the basket. The apparatus was maintained at 37 °C±0.5 °C. 
The dissolution was carried out in 250 ml of 0.1 N HCl with 2% SLS 
for 2h followed by 250 ml of phosphate buffer (pH 6.8) with 2% SLS 
for additional 4 h followed by phosphate buffer 7.4 with 2% SLS for 
additional 18 h. Aliquot (5 ml) was withdrawn from the dissolution 
apparatus at specific time intervals of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 24 
h, filtered through 0.45-micron syringe filter and analyzed using RP-
HPLC. Sink conditions were maintained by replenishing the same 
amount of medium. The study was performed in triplicate (n=3).  
RESULTS AND DISCUSSION 
Optimization of chromatographic conditions 
A mobile phase composition of acetonitrile: water: methanol 
(50:10:40 v/v/v/) at a flow rate was at 0.5 ml/min and Eclipse XDB-
C18 (4.6 x 150 mm, 5 µ) column maintained at 70 °C±0.02 °C were 
found optimum for to get reproducible peaks with symmetry with 
limits. The optimized chromatogram of standard curcumin and 
cyclosporine (100 μg/ml) is given in fig. 2. 
 
 
Fig. 2: Chromatogram of standard curcumin and cyclosporine in optimized chromatographic conditions 
 
System suitability  
The system suitability parameters like tailing factor were found to 
be less than 2, theoretical plates were not less than 2000 and 
resolution was found to be more than 2. All the parameters were 
fulfilled as per USP acceptance criteria.  
The results of system suitability are expressed in table 1. 
 
Table 1: Results of system suitability parameters for curcumin and cyclosporine 
Parameters Curcumin Cyclosporine Acceptance criteria 
Retention time 3.047±0.05 6.587±0.01 -- 
Resolution 9.874±0.01 Rs>2 
No. of theoretical Plates 2874±0.06 2589±0.04 N>2000 
Tailing Factor 0.764±0.02 0.981±0.01 T<1.5 
Peak area 63838533±218 1368407±4291 -- 
*The data is expressed as mean±SD, *n: 6 i.e. number of injections, *SD: standard deviation 
 
 
Fig. 3: HPLC chromatogram of placebo (pellets of excipients dissolved in mobile phase) 
 
Specificity 
The optimized method was found to be specific as there was no 
interference of the mobile phase at the retention time of both the drugs. 
Chromatogram indicating the specificity of the method is shown in fig. 3. 
Precision 
Repeatability studies, intraday precision, and inter-day precision 
studies were performed for curcumin and cyclosporine and the % 
RSD values were found to be<2% for both the drugs. Thus, the 
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developed method was found to be precise. Results for precision are expressed in table 2. 
  
Table 2: Results of the precision study 
Precision parameters  Curcumin Cyclosporine 
Repeatability Peak area 6408248±5849 1357613±1463 
% RSD 0.9128 1.0782 
Intraday study 
(n=6) 
Peak area: Time 1 6414627 1355923 
Peak area: Time 2 6454088 1345019 
Peak area: Time 3 6434833 1345788 
Pooled mean±SD of three-time points 6434516±17649 1348910±5443 
% RSD 0.2742 0.4035 
Interday study 
(n=6) 
Peak area: Day 1 6391294 1351098 
Peak area: Day 2 1352103 1352103 
Peak area: Day 3 1362419 1362419 
Pooled mean±SD of three days 6424627±288 1355206±626 
% RSD  0.44931 0.4624 
*The data is expressed as mean±SD, *n: 6 i.e. number of injections, *SD: standard deviation, *%RSD: percentage relative standard deviation 
 
Accuracy 
The mean recovery for curcumin and cyclosporine was calculated at 
three different levels. The percentage recovery was found to be 
between 97-103% for all three-level and % RSD were found to be 
less than 2. The results obtained for recovery at 80%, 100%, and 
120% was found to be within the specified limits.  
Hence the method was found to be accurate. Results for accuracy are 
expressed in table 3 and chromatograms are given in fig. 4. 
 
Table 3: Accuracy studies for curcumin and cyclosporine 
 Level Amount added (mg/ml) Amount found (mg/ml) % recovery %RSD 
Curcumin 80% 19.2 19.298 100.67%±0.0020 0.2067 
100 24 24.04 100.09%±0.0009 0.09283 
120% 28.8 28.58 99.73%±0.0075 0.7592 
Cyclosporine 80% 9.6 11.93 100.39%±0.0058 0.5862 
100 12 11.92 99.50%±0.0017 0.1011 
120% 14.4 14.43 100.13%±0.0005 0.05765 
*The data is expressed as mean±SD, *n: 3 i.e. number of injections, *SD: standard deviation, *%RSD: percentage relative standard deviation 
 
 
Fig. 4: Chromatogram of curcumin and cyclosporine in accuracy studies at (a) Level 1: 80%, (b) Level 2: 100% and (c) Level 3: 120% 
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Linearity and range 
In order to test the linearity of the method, six dilutions of the working 
standard solutions for the drugs curcumin and cyclosporine in the 
range of 8-48 μg/ml and 4-24 μg/ml were prepared. Each of the 
dilutions was injected for the three times (n=3) into the column. 
Correlation coefficient (R2) should be above 0.99 for both the drugs. 
The correlation coefficients (R2 value) of developed method for both 
the drugs were found to be within specified limits. Linearity curves are 




Fig. 5: Linearity curve of (a) curcumin and (b) cyclosporine, (*n: 3 i.e. number of injections of each concentration. The data is expressed in 
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Fig. 6: Linearity study chromatogram of (a) curcumin 8 µg/ml and cyclosporine 4 µg/ml, (b) curcumin 16 µg/ml and cyclosporine 8 µg/ml, 
(c) curcumin 24 µg/ml and cyclosporine 12 µg/ml, (d) curcumin 32 µg/ml and cyclosporine 16 µg/ml, (e) curcumin 40 µg/ml and 
cyclosporine 20 µg/ml, and (f) curcumin 48 µg/ml and cyclosporine 24 µg/ml 
 
LOD and LOQ 
On the basis of peak response and slope of the regression equation, 
LOD and LOQ was calculated. The LOD of curcumin and cyclosporine 
was found to be 0.3594 µg/ml and 0.1839 µg/ml respectively. The 
LOQ of curcumin and cyclosporine was found to be 1.0892 µg/ml 
and 0.5575 µg/ml respectively.  
Robustness 
The method was found to be robust enough that the peak area was 
not apparently affected by small variation in the chromatographic 
conditions. On the evaluation of the results, it was concluded that 
the variation in the flow rate and variation in the temperature does 
not affect the method significantly. Hence, it was indicated that the 
method was robust even by a change in these two parameters. The 
system suitability parameters were within the limits and results for 
robustness is shown in table 4. 
Drug content 
Drug content of the formulation was found to be 97.34±0.5% for 
curcumin and 95.68±0.63% for cyclosporine. Hence it complies with 
the Pharmacopoeial limit of assay of drugs (90%-110%). 
Desai et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 2, 26-33 
 
32 
Table 4: Robustness study by varying flow rate and temperature 
  Curcumin Cyclosporine 
Variable Level (±) Mean Retention time (min)±SD % RSD Mean Retention time (min)±SD % RSD 
Flow rate (ml) 0.4 ml 3.14±0.005 0.184 6.61±0.005 0.087 
0.6 ml 2.9±0.005 0.199 6.55±0.005 0.088 
Temperature (°C)  69 °C 3.043±0.001 0.056 6.58±0.005 0.087 
71 °C 3.04±0.0005 0.018 6.60±0.005 0.087 
*The data is expressed as mean±SD, *n: 3 i.e. number of injections at each level, *SD: standard deviation, *%RSD: percentage relative standard 
deviation 
 
In vitro dissolution study 
In vitro dissolution studies were performed 20% weight gain of 
pellets after coating with Eudragit S100. Curcumin and cyclosporine 
showed better drug release at 20% weight gain of pellets after 
coating with pH-sensitive polymer Eudragit S100. The in vitro 
dissolution profile of curcumin and cyclosporine in capsule 
formulation estimated using developed HPLC method is shown in 
fig. 7. During the acidic stage (gastric stage), cyclosporine and 
curcumin did not show any release at the end of 2 h. At the buffer 
stage (Intestinal stage), less than 15% release of both the drugs was 
observed at the end of 6h. At the end of 24h, almost 80% of 
curcumin and cyclosporine was released which was desirable. Thus, 
the developed HPLC method was successfully applied for the 
determination of drug release of curcumin and cyclosporine from 
the capsule dosage form in a dissolution study. 
 
 
Fig. 7: In vitro drug release study of curcumin and cyclosporine in a capsule formulation using developed RP-HPLC method (*n: 3 i.e. no. of 
capsule formulation tested at each time interval. The data is expressed in graph as mean±SD, *SD: standard deviation) 
 
DISCUSSION 
A novel, rapid and reproducible RP-HPLC method for simultaneous 
estimation of curcumin and cyclosporine in capsule dosage form has 
been developed and validated as per ICH Guidelines. The validation 
acceptance criteria were satisfied in all cases as per USP/ICH 
guidelines. Application of this method for estimation of curcumin 
and cyclosporine from capsule dosage form showed that the 
excipients did not interfere in the estimation of both the drugs. 
Hence, this method was specific. The sample recoveries in the 
formulation were in good agreement and they suggested non-
interference of formulation excipients in the estimation. The results 
obtained from the above set of observations prove that the present 
RP-HPLC method developed for the quantitative determination of 
curcumin and cyclosporine in the formulation was simple, sensitive, 
accurate, precise and robust. Moreover, various analytical methods 
for estimation of curcumin and cyclosporine alone were reported 
and in combination with other drugs [8]. However, there is no RP-
HPLC method for simultaneous estimation of curcumin and 
cyclosporine in combination along with drug release analysis from 
the capsule dosage form and the novel method developed in this 
report is the first of its kind. The developed method is based on the 
use of a very economical solvent, had short chromatographic time 
and hence can be performed with ease. 
CONCLUSION  
A simple, specific, accurate, precise analytical method was developed. 
The proposed method presented the ability to separate curcumin and 
cyclosporine when used in combination in a dosage form using RP-
HPLC method. It was successfully validated as per ICH-guidelines. 
Hence it can be concluded that this method can be easily adopted for 
routine analysis and quality control of curcumin and cyclosporine 
fixed-dose combination pharmaceutical dosage forms and API.  
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